We have reviewed a great many GLP-1 providers, and nearly all of them explain who is a good candidate. MD365 is one of the very few that publishes who is not — by name, by condition. That is the single most useful thing a page like this can carry.
It Tells You Who Should Not Take This
The listed contraindications are a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, active pancreatitis and severe liver disease.
These are the real ones. Medullary thyroid carcinoma and MEN2 carry a boxed warning on this drug class, and pancreatitis is the adverse event most likely to require stopping treatment. A patient reading this page learns something that could genuinely prevent harm — before booking, not after.
Set that against what most of this category publishes. We reviewed one service whose entire intake is advertised as two minutes, with no eligibility criteria and no contraindications anywhere. Marketing pages almost universally describe the upside and leave the exclusions to a form you fill in later, if at all. Publishing them up front costs a company customers, which is precisely why so few do it.
MD365 also describes candidacy sensibly — adults with obesity or high body weight, type 2 diabetes or prediabetes, cardiovascular risk factors, or a history of unsuccessful weight management. That last one matters: these medications are indicated after lifestyle attempts, not instead of them. Our GLP-1 eligibility guide covers the criteria in full.
It Handles the Prior Authorisation
MD365 states that it handles checking your benefits and prior authorisations.
This is the second provider in our entire review set to offer it — the other being The Virtual NP — and it is worth more than almost any feature a competitor advertises. Prior authorisation is the actual barrier between having insurance and having covered medication: plans that cover Wegovy or Zepbound typically demand documented BMI, prior weight-loss attempts and comorbidities, submitted by a prescriber and frequently appealed once before approval.
It is unpaid administrative work, which is why the cash-pay compounded market routes around insurance entirely rather than doing it. A practice willing to fight that paperwork can turn a $1,000-plus monthly list price into a copay, and that swing dwarfs the difference between any two compounded sellers. Our GLP-1 insurance coverage guide covers what plans typically ask for.
Both Routes, Honestly Separated
The offering splits cleanly: brand-name Wegovy, Ozempic, Mounjaro and Zepbound via insurance, or compounded semaglutide and tirzepatide described as aggressively priced, shipped as pre-filled syringes to your home.
Naming all four brands and keeping them separate from the compounded alternatives is the disclosure we keep asking for, and it lets a patient make the trade knowingly rather than discovering it later. Pre-filled syringes are also a practical detail worth noting — they remove the drawing-up step that multi-dose vials require, which is where compounded dosing errors have occurred.
One caveat on the brand list: Ozempic and Mounjaro are approved for type 2 diabetes, while Wegovy and Zepbound are the same molecules approved for weight management. Listing all four together is common practice, but if you do not have diabetes, the weight-management approvals are the relevant ones and prescribing the diabetes versions for weight loss is off-label — worth raising explicitly with the prescriber.
The practice runs 11 locations across Nassau and Suffolk Counties on Long Island, with check-ins offered in person or by telehealth, and optional remote coordination of blood work. It has operated since 2019.
A 503B Pharmacy Is Not FDA-Approved
The compounded products are described as coming through an “FDA-approved 503b pharmacy”. That phrase does not describe anything the FDA does.
503B outsourcing facilities register with the FDA and are subject to inspection and current good manufacturing practice requirements. Registration is a filing, not an approval. And the agency states plainly that it does not review compounded preparations for safety, effectiveness or quality at all.
This is worth naming precisely because the underlying fact is genuinely good news. A 503B outsourcing facility is a higher-oversight route than a 503A pharmacy — it operates under manufacturing-quality requirements and FDA inspection, which is a real distinction and one most sellers never mention. MD365 has something worth saying and has overstated it. We found the same error at Marek Health, which described its pharmacies as “FDA-approved” too.
The accurate phrasing would be “FDA-registered 503B outsourcing facility”. The difference matters because “FDA-approved” sitting beside a medication reads as a statement about the drug, and for a compounded product it never is.
And Not One Price
For all the clinical candour, no pricing appears anywhere — not for the brand-name route, not for the compounded one, not for consultations. Costs are said to vary with insurance coverage and dosage, and the compounded option is called “aggressively priced” without a figure attached.
For the brand-name route this is partly defensible: what you pay depends on your plan, and MD365 does not set it. For the compounded route it is not. That price is entirely within the practice’s control, and “aggressively priced” is a claim about cost made without the cost — unverifiable against Ozari’s $86 or anyone else’s published figure.
No BMI threshold, insurance carrier list, HSA or FSA position or specific lab requirement is published either. Ask for the compounded monthly price and your likely copay on the brand route at first contact.
Provider Facts
| Medications offered | Brand-name Wegovy, Ozempic, Mounjaro and Zepbound via insurance, plus compounded semaglutide and tirzepatide as pre-filled syringes |
|---|---|
| Brand-name or compounded | Both, clearly separated; the compounding partner is described as a 503B pharmacy, though characterised as FDA-approved rather than FDA-registered |
| Consultation process | Online booking or virtual visit, reviewing medical history, medications and health goals; fee not published |
| Eligibility | Candidacy described in terms of obesity, type 2 diabetes or prediabetes and cardiovascular risk; contraindications published, but no BMI threshold stated |
| Provider involvement | Regular check-ins in person or by telehealth; practice established 2019 |
| Lab requirements | Optional remote coordination for essential testing such as blood work; requirements and cost not published |
| Pharmacy fulfillment | A 503B outsourcing facility for compounded products; not individually named |
| Shipping frequency | Pre-filled syringes shipped directly to your home |
| Support services | Benefits checking and prior authorisation handling, plus ongoing check-ins |
| Membership fees | Not published |
| Medication fees | Not published for either route; the compounded option is described only as aggressively priced |
| Cancellation policy | Not published |
| Refund policy | Not published |
| Insurance | Brand-name medication supplied through insurance, with benefits checking and prior authorisations handled by the practice; carriers not listed |
| HSA/FSA | Not published |
| Availability | New York only - 11 locations across Nassau and Suffolk Counties, Long Island |
Pros and Cons
Pros
- Publishes real contraindications — MTC, MEN2, pancreatitis, severe liver disease
- Handles benefits checking and prior authorisations, which almost nobody does
- Names all four brand-name products and separates them from compounded options
- Uses a 503B outsourcing facility, a higher-oversight compounding route
- Pre-filled syringes rather than draw-your-own vials
- 11 Long Island locations with in-person or telehealth follow-up
- Frames candidacy around prior unsuccessful weight management, not just desire
Cons
- No pricing published for any route, including the compounded one it controls
- Calls the compounded option “aggressively priced” without a figure
- Describes a 503B pharmacy as FDA-approved, which the FDA does not do
- Lists diabetes-indicated products alongside weight-management ones without distinguishing them
- No BMI threshold, insurance carrier list or HSA/FSA position
- New York only
Who It May Be Best For
A strong fit if you are on Long Island with insurance that might cover a GLP-1. The combination of brand-name access and prior authorisation handling is the most valuable thing on offer here, and very few competitors provide it.
Also good if you want a practice that will tell you plainly whether you should be taking this at all — the published contraindications signal a clinical rather than purely commercial posture.
Ask for the compounded price before assuming “aggressively priced” means competitive. Published rates elsewhere start at $86 a month, so you have a benchmark to hold it against.
If you have any thyroid cancer history in your family, raise it explicitly. MD365 lists it as a contraindication, which is the right answer — make sure it is asked.
Alternatives
The Virtual NP also handles prior authorisations and publishes its own fees. knownwell bills insurance directly. Ozari Health publishes compounded prices outright. Our best online GLP-1 providers page ranks the field.
Limitations of This Review
Based on MD365’s own published materials at md365.org, checked on 6 September 2026. Anything marked not published means we could not find it, and pricing is very likely quoted at consultation. The published contraindication list is not exhaustive — full prescribing information contains more, and only a clinician who knows your history can assess you. Our description of what 503B registration means and of what the FDA does and does not approve reflects the agency’s own published position, not a claim by MD365. Nothing here is medical advice.
Frequently Asked Questions
Who should not take a GLP-1?
MD365 lists a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, active pancreatitis and severe liver disease. The first two carry a boxed warning for this drug class. The list is not exhaustive — a clinician who knows your history has to assess you.
Will it help with insurance?
It states that it handles benefits checking and prior authorisations. That is the work that decides whether a plan actually covers a GLP-1, and almost no cash-pay competitor will do it.
Is a 503B pharmacy FDA-approved?
No. 503B outsourcing facilities register with the FDA and are inspected under manufacturing-quality requirements — genuinely more oversight than a 503A pharmacy, but registration is not approval, and the FDA does not review compounded preparations for safety, effectiveness or quality.
What does it cost?
Not published for either route. The compounded option is described as aggressively priced without a number, and brand-name cost depends on your plan. Ask for both figures at first contact.
Verdict
3.5 / 5 — no pricing published; brand-name via insurance
Clinically the most candid provider in this round — real contraindications, prior authorisation handling, both medication routes named and separated. Undercut by publishing no prices at all and by describing a registered 503B facility as FDA-approved.
The point worth carrying beyond this provider: a page that tells you who should not take the drug is worth more than one that tells you how quickly you can start. Exclusions cost a seller customers, so publishing them is the disclosure with the clearest incentive against it — and therefore the most informative when you find it.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from MD365's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026